HC Wainwright Has Optimistic Outlook of CAPR FY2024 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Capricor Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of ($1.33) per share for the year, up from their prior forecast of ($1.38). HC Wainwright has a “Buy” rating and a $77.00 price objective on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.11) EPS.

A number of other research firms have also commented on CAPR. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price objective on the stock. Oppenheimer restated an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. Cantor Fitzgerald increased their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Finally, Maxim Group upped their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Down 1.2 %

Shares of NASDAQ:CAPR opened at $18.38 on Monday. The business has a fifty day simple moving average of $15.21 and a 200 day simple moving average of $8.50. Capricor Therapeutics has a 12-month low of $2.87 and a 12-month high of $23.40. The firm has a market cap of $834.56 million, a P/E ratio of -17.34 and a beta of 4.00.

Institutional Trading of Capricor Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CAPR. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics during the first quarter worth $40,000. Main Street Financial Solutions LLC grew its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter valued at about $133,000. Bank of New York Mellon Corp lifted its position in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Capricor Therapeutics during the third quarter valued at about $161,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The stock was acquired at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the purchase, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This trade represents a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 12.00% of the stock is currently owned by company insiders.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.